Peter Grant

Prognostic gene expression signature for high-grade serous ovarian cancer

J Millstein, T Budden, EL Goode, MS Anglesio, A Talhouk, MP Intermaggio, HS Leong, S Chen, W Elatre, B Gilks, T Nazeran, M Volchek, RC Bentley, C Wang, DS Chiu, S Kommoss, SCY Leung, J Senz, A Lum, V Chow, et al.

Journal article  |  2020  |  Annals of Oncology

BACKGROUND: Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies ..

Evaluating the impact of dose reductions and delays on progression-free survival in women with ovarian cancer treated with either three-weekly or dose-dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort study

T Sivakumaran, L Mileshkin, P Grant, L Na, A DeFazio, M Friedlander, A Obermair, PM Webb, G Au-Yeung

Journal article  |  2020  |  Gynecologic Oncology

OBJECTIVES: To determine the impact of chemotherapy dose reductions and dose delays on progression-free survival (PFS) in women wi..

Does physical activity improve chemotherapy completion in women receiving chemotherapy for ovarian cancer?

Vanessa L Beesley, Tanya L Ross, Nina Renhua Na, Tharani Sivakumaran, George Au-Yeung, Christina M Nagle, Anna deFazio, Peter Grant, Andreas Obermair, Michael Friedlander, Penelope Webb

Conference Proceedings  |  2019  |  ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY

PARAGON: A Phase II study of anastrozole in patients with estrogen receptor-positive recurrent/metastatic low-grade ovarian cancers and serous borderline ovarian tumors

Monica Tang, Rachel L O'Connell, Frederic Amant, Philip Beale, Orla McNally, Katrin M Sjoquist, Peter Grant, Alison Davis, Peter Sykes, Linda Mileshkin, Tania Moujaber, Catherine J Kennedy, Anna deFazio, King Tan, Yoland Antill, Jeffrey Goh, Tony Bonaventura, James Scurry, Michael Friedlander

Journal article  |  2019  |  Gynecologic Oncology

OBJECTIVE: Treatment options are limited for patients with recurrent/metastatic low-grade ovarian cancers (LGOCs) and serous borde..

Comparing the impact of dose reductions and delays on ovarian cancer patient outcomes with three-weekly versus dose dense carboplatin and paclitaxel regimens in the national prospective OPAL cohort.

Tharani Sivakumaran, Linda R Mileshkin, Peter T Grant, Michael Friedlander, Penelope M Webb, George Au-Yeung

Conference Proceedings  |  2018  |  Journal of Clinical Oncology

Improved quality of risk-reducing salpingo-oophorectomy in Australasian women at high risk of pelvic serous cancer

YC Lee, M Bressel, P Grant, P Russell, C Smith, S Picken, S Camm, BE Kiely, RL Milne, SA McLachlan, M Hickey, ML Friedlander, JL Hopper, KA Phillips

Journal article  |  2017  |  Familial Cancer

Paragon (ANZGOG-0903): Phase 2 Study of Anastrozole in Women With Estrogen or Progesterone Receptor-Positive Platinum-Resistant or -Refractory Recurrent Ovarian Cancer

Anthony Bonaventura, Rachel L O'Connell, Cristina Mapagu, Philip J Beale, Orla M McNally, Linda R Mileshkin, Peter T Grant, Alison M Hadley, Jeffery CH Goh, Katrin M Sjoquist, Julie Martyn, Anna DeFazio, James Scurry, Michael L Friedlander

Journal article  |  2017  |  International Journal of Gynecological Cancer

Oral cyclophosphamide in recurrent ovarian cancer

Despina Handolias, Michael Quinn, Serene Foo, Linda Mileshkin, Peter Grant, Gaelle Dutu, Danny Rischin

Journal article  |  2016  |  Asia-Pacific Journal of Clinical Oncology

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer.

Paul Lr Mitchell, Michael A Quinn, Peter T Grant, David G Allen, Thomas W Jobling, Shane C White, Anne Zhao, Vaios Karanikas, Hilary Vaughan, Geoffrey Pietersz, Ian Fc McKenzie, Sharron E Gargosky, Bruce E Loveland

Journal article  |  2014  |  Journal for ImmunoTherapy of Cancer

BACKGROUND: Mucin 1 antigen, highly expressed by epithelial ovarian cancer (EOC), is a potential target for immunotherapy. A previ..

Phase II biomarker trial of a multimarker diagnostic for ovarian cancer

Tracey Edgell, G Martin-Roussety, G Barker, DJ Autelitano, D Allen, P Grant, GE Rice

Journal article  |  2010  |  Journal of Cancer Research and Clinical Oncology